IndustryCompany release

Arvinas doses first patients with HPK1 degrader ARV-6723; cash of $558.9M lasts into 2H 2028

🇺🇸 Arvinas, Inc. (ARVN) · Tue 03 Nov 2026

The protein degrader developer reported Q3 2026 results, with ARV-6723 in a Phase 1/2 solid tumour trial and EU and UK filings planned for ARV-102 in PSP.

Arvinas reported its third-quarter 2026 results on 3 November 2026. The company said it has begun dosing patients in a Phase 1/2 trial of ARV-6723, an oral degrader of HPK1, in advanced solid tumours.

The company also presented biomarker data for ARV-102 in Parkinson's disease. It plans to submit clinical trial applications in the EU and the UK for ARV-102 in progressive supranuclear palsy (PSP). The US investigational new drug application for that indication remains on hold.

Arvinas held cash of $558.9 million at 30 September 2026. The company says this funds operations into the second half of 2028. Both research and development expenses and general and administrative expenses fell compared with the same quarter a year earlier.

The source text was not available for this report, so detailed financial figures, trial design and the reasons for the US hold are not covered here.

What it means for your team

  • The US IND hold for ARV-102 in PSP continues, so ex-US submissions in the EU and UK are the next regulatory step for that programme.
  • Teams tracking EU and UK trial applications should watch for the ARV-102 PSP filings, which the company plans but has not yet dated.
  • ARV-6723 is now in patient dosing, so it moves from preclinical to early clinical safety and activity monitoring.
  • The cash runway into 2H 2028 suggests the company can fund its current development plans for about two years, which is relevant to partnering and supply planning.

Company's press release (SEC filing): Arvinas, Inc. ↗

Article written by VigiEye from the official source (Arvinas, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →